Monogram Technologies Releases 2024 Financial Overview

Monogram Technologies, a company specializing in AI-driven robotics for orthopedic surgery, has disclosed its full-year financial results for 2024. The firm completed critical supplemental testing and responded to the FDA's Additional Information Request regarding its mBôs™ Total Knee Arthroplasty System. The company aims for FDA clearance to commercialize its product in the U.S.

Monogram's strategic collaboration with Shalby Limited involves conducting clinical trials in India. A significant $13 million public offering was executed, supporting these endeavors. Financially, Monogram's R&D expenses dropped to $8.8 million, a 17% decline from 2023, while its net loss increased to $16.3 million for 2024.

Optimistically, the company remains focused on commercial and international expansion. Management anticipates favorable FDA decisions, allowing the TKA System's U.S. market entry.